FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Georges Gharabawi

Research Profile

Chemicals & Drugs

Disorders

Procedures

Concepts & Ideas

Activities & Behaviors

Schizophrenic Psychology

Co-author Network

Publications

TOP 3
Aaron S Kemp; Nina R Schooler; Amir H Kalali; Larry Alphs; Ravi Anand; George Awad; Michael Davidson; Sanjay Dubé; Larry Ereshefsky; Georges Gharabawi; Andrew C Leon; Jean-Pierre Lepine; Steven G Potkin; An Vermeulen
What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it?
Gahan J Pandina; Dennis A Revicki; Leah Kleinman; Ibrahim Turkoz; Jasmanda H Wu; Mary J Kujawa; Ramy Mahmoud; Georges Gharabawi
Patient-rated troubling symptoms of depression instrument results correlate with traditional clinician- and patient-rated measures: a secondary analysis of a randomized, double-blind, placebo-controlled trial.
Marilyn Ader; W Timothy Garvey; Lawrence S Phillips; Charles Nemeroff; Georges Gharabawi; Ramy A Mahmoud; Andrew Greenspan; Sally A Berry; Dominique L Musselman; Jacqueline Morein; Young Zhu; Lian Mao; Richard N Bergman
Ethnic heterogeneity in glucoregulatory function during treatment with atypical antipsychotics in patients with schizophrenia.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Georges Gharabawi (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2010: Aaron S Kemp; Nina R Schooler; Amir H Kalali; Larry Alphs; Ravi Anand; George Awad; Michael Davidson; Sanjay Dubé; Larry Ereshefsky; Georges Gharabawi; Andrew C Leon; Jean-Pierre Lepine; Steven G Potkin; An Vermeulen
What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it?
Schizophrenia bulletin 2010;36(3):504-9.
2009: Gahan J Pandina; Dennis A Revicki; Leah Kleinman; Ibrahim Turkoz; Jasmanda H Wu; Mary J Kujawa; Ramy Mahmoud; Georges Gharabawi
Patient-rated troubling symptoms of depression instrument results correlate with traditional clinician- and patient-rated measures: a secondary analysis of a randomized, double-blind, placebo-controlled trial.
Journal of affective disorders 2009;118(1-3):139-46.
2008: Marilyn Ader; W Timothy Garvey; Lawrence S Phillips; Charles Nemeroff; Georges Gharabawi; Ramy A Mahmoud; Andrew Greenspan; Sally A Berry; Dominique L Musselman; Jacqueline Morein; Young Zhu; Lian Mao; Richard N Bergman
Ethnic heterogeneity in glucoregulatory function during treatment with atypical antipsychotics in patients with schizophrenia.
Journal of psychiatric research 2008;42(13):1076-85.
2008: Marci L Chew; Benoit H Mulsant; Bruce G Pollock; Mark E Lehman; Andrew Greenspan; Ramy A Mahmoud; Margaret A Kirshner; Denise Sorisio; Robert R Bies; Georges Gharabawi
Anticholinergic activity of 107 medications commonly used by older adults.
Journal of the American Geriatrics Society 2008;56(7):1333-41.
2008: Gahan J Pandina; Dennis A Revicki; Leah Kleinman; Ibrahim Turkoz; Jasmanda Wu; Ramy Mahmoud; Georges Gharabawi
Psychometric evaluation of a patient-rated troubling symptom scale for generalized anxiety disorder clinical trials.
Psychopharmacology bulletin 2008;41(3):68-90.
2008: George S Alexopoulos; Carla M Canuso; Georges Gharabawi; Cynthia A Bossie; Andrew Greenspan; Ibrahim Turkoz; Charles Reynolds
Placebo-controlled study of relapse prevention with risperidone augmentation in older patients with resistant depression.
The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 2008;16(1):21-30.
2007: Georges Gharabawi; Cynthia A Bossie; Ibrahim Turkoz; Mary Kujawa; Ramy A Mahmoud; George Simpson
The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable.
The Journal of nervous and mental disease 2007;195(12):976-82.
2007: Marcia F T Rupnow; Andrew Greenspan; Georges Gharabawi; Colette Kosik-Gonzalez; Young Zhu; Stephen M Stahl
Incidence and costs of polypharmacy: data from a randomized, double-blind, placebo-controlled study of risperidone and quetiapine in patients with schizophrenia or schizoaffective disorder.
Current medical research and opinion 2007;23(11):2815-22.
2007: Philip D Harvey; Howard Hassman; Lian Mao; Georges Gharabawi; Ramy A Mahmoud; Luella M Engelhart
Cognitive functioning and acute sedative effects of risperidone and quetiapine in patients with stable bipolar I disorder: a randomized, double-blind, crossover study.
The Journal of clinical psychiatry 2007;68(8):1186-94.
2007: Gahan J Pandina; Robert Bilder; Philip D Harvey; Richard S E Keefe; Michael G Aman; Georges Gharabawi
Risperidone and cognitive function in children with disruptive behavior disorders.
Biological psychiatry 2007;62(3):226-34.
2007: Georges Gharabawi; Cynthia A Bossie; Gahan J Pandina; Mary Kujawa; Andrew Greenspan; Young Zhu
A discussion of 2 double-blind studies comparing risperidone and quetiapine in patients with schizophrenia.
The Journal of clinical psychiatry 2007;68(2):333; author reply 334.
2007: Gahan J Pandina; Cynthia A Bossie; Young Zhu; Georges Gharabawi
Evaluating movement disorders in pediatric patients receiving risperidone: a comparison of spontaneous reports and research criteria for TD.
Child and adolescent psychiatry and mental health 2007;1(1):3.
2007: Georges Gharabawi; Natalie C Gearhart; Robert A Lasser; Ramy A Mahmoud; Young Zhu; Erik Mannaert; Ineke Naessens; Cynthia A Bossie; Mary Kujawa; George M Simpson
Maintenance therapy with once-monthly administration of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder: a pilot study of an extended dosing interval.
Annals of general psychiatry 2007;6():3.
2007: John P Docherty; Cynthia A Bossie; Bernard Lachaux; Philippe Bouhours; Young Zhu; Robert A Lasser; Georges Gharabawi
Patient-based and clinician-based support for the remission criteria in schizophrenia.
International clinical psychopharmacology 2007;22(1):51-5.
2006: Marci L Chew; Benoit H Mulsant; Bruce G Pollock; Mark E Lehman; Andrew Greenspan; Margaret A Kirshner; Robert R Bies; Shitij Kapur; Georges Gharabawi
A model of anticholinergic activity of atypical antipsychotic medications.
Schizophrenia research 2006;88(1-3):63-72.
2006: Mark Hyman Rapaport; Georges Gharabawi; Carla M Canuso; Ramy A Mahmoud; Martin B Keller; Cynthia A Bossie; Ibrahim Turkoz; Robert A Lasser; Amy Loescher; Philippe Bouhours; Fiona Dunbar; Charles Nemeroff
Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2006;31(11):2505-13.
2006: George M Simpson; Ramy A Mahmoud; Robert A Lasser; Mary Kujawa; Cynthia A Bossie; Ibrahim Turkoz; Steven Rodriguez; Georges Gharabawi
A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder.
The Journal of clinical psychiatry 2006;67(8):1194-203.
2006: Steven G Potkin; Georges Gharabawi; Andrew Greenspan; Ramy A Mahmoud; Colette Kosik-Gonzalez; Marcia F T Rupnow; Cynthia A Bossie; Michael Davidson; Victoria Burtea; Young Zhu; Jintendra K Trivedi
A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization.
Schizophrenia research 2006;85(1-3):254-65.
2006: Georges Gharabawi; Robert A Lasser; Cynthia A Bossie; Young Zhu; Xavier Amador
Insight and its relationship to clinical outcomes in patients with schizophrenia or schizoaffective disorder receiving long-acting risperidone.
International clinical psychopharmacology 2006;21(4):233-40.
2006: Georges Gharabawi; Cynthia A Bossie; Young Zhu
New-onset tardive dyskinesia in patients with first-episode psychosis receiving risperidone or haloperidol.
The American journal of psychiatry 2006;163(5):938-9.
2006: Jacobo E Mintzer; Andrew Greenspan; Ivo Caers; Ilse Van Hove; Stuart Kushner; Myron Weiner; Georges Gharabawi; Lon S Schneider
Risperidone in the treatment of psychosis of Alzheimer disease: results from a prospective clinical trial.
The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 2006;14(3):280-91.
2006: Georges Gharabawi; Andrew Greenspan; Marcia F T Rupnow; Colette Kosik-Gonzalez; Cynthia A Bossie; Young Zhu; Amir Kalali; A George Awad
Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: data from a randomized double-blind trial.
BMC psychiatry 2006;6():45.
2006: Georges Gharabawi; Cynthia A Bossie; Ramy A Mahmoud; Carla M Canuso; Robert A Lasser; Ibrahim Turkoz; Andrew Greenspan
Methodological issues in a comparative study of ziprasidone and risperidone.
The Journal of clinical psychiatry 2006;67(1):162-3; author reply 163-4.
2005: Steven G Potkin; Georges Gharabawi; Andrew Greenspan; Marcia F T Rupnow; Colette Kosik-Gonzalez; Gary Remington; Charles Ruetsch; Dennis Revicki
Psychometric evaluation of the Readiness for Discharge Questionnaire.
Schizophrenia research 2005;80(2-3):203-12.
2005: Andrew Greenspan; Georges Gharabawi; Joseph Kwentus
Thyroid dysfunction during treatment with atypical antipsychotics.
The Journal of clinical psychiatry 2005;66(10):1334-5.
2005: Georges Gharabawi; Cynthia A Bossie; Robert A Lasser; Ibrahim Turkoz; Stephen Rodriguez; Guy Chouinard
Abnormal Involuntary Movement Scale (AIMS) and Extrapyramidal Symptom Rating Scale (ESRS): cross-scale comparison in assessing tardive dyskinesia.
Schizophrenia research 2005;77(2-3):119-28.
2005: Georges Gharabawi; Cynthia A Bossie; Young Zhu; Lian Mao; Robert A Lasser
An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study.
Schizophrenia research 2005;77(2-3):129-39.
2005: Robert A Lasser; Cynthia A Bossie; Georges Gharabawi; John M Kane
Remission in schizophrenia: Results from a 1-year study of long-acting risperidone injection.
Schizophrenia research 2005;77(2-3):215-27.
2005: Robert A Lasser; Cynthia A Bossie; Georges Gharabawi; Ross J Baldessarini
Clinical improvement in 336 stable chronically psychotic patients changed from oral to long-acting risperidone: a 12-month open trial.
The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP) 2005;8(3):427-38.
2004: Benoit H Mulsant; Georges Gharabawi; Cynthia A Bossie; Lian Mao; Rick A Martinez; Larry E Tune; Andrew Greenspan; Jeni N Bastean; Bruce G Pollock
Correlates of anticholinergic activity in patients with dementia and psychosis treated with risperidone or olanzapine.
The Journal of clinical psychiatry 2004;65(12):1708-14.
2004: Robert A Lasser; Cynthia A Bossie; Georges Gharabawi; Mariëlle Eerdekens; Henry A Nasrallah
Efficacy and safety of long-acting risperidone in stable patients with schizoaffective disorder.
Journal of affective disorders 2004;83(2-3):263-75.
2004: Michael G Aman; Georges Gharabawi
Treatment of behavior disorders in mental retardation: report on transitioning to atypical antipsychotics, with an emphasis on risperidone.
The Journal of clinical psychiatry 2004;65(9):1197-210.
2004: Robert A Lasser; Cynthia A Bossie; Young Zhu; Georges Gharabawi; Mariëlle Eerdekens; Michael Davidson
Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder.
International journal of geriatric psychiatry 2004;19(9):898-905.
2004: Robert A Lasser; Cynthia A Bossie; Georges Gharabawi; Martin Turner
Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone.
European psychiatry : the journal of the Association of European Psychiatrists 2004;19(4):219-25.
2004: Fred Grossman; Akiko Okamoto; Ibrahim Turkoz; Georges Gharabawi
Risperidone in the treatment of elderly patients with psychosis of Alzheimer's disease and related dementias.
Journal of the American Geriatrics Society 2004;52(5):852-3.
2004: Glenn W Currier; James C-Y Chou; David Feifel; Cynthia A Bossie; Ibrahim Turkoz; Ramy A Mahmoud; Georges Gharabawi
Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam.
The Journal of clinical psychiatry 2004;65(3):386-94.
2004: Robert A Lasser; Lian Mao; Georges Gharabawi
Smokers and nonsmokers equally affected by olanzapine-induced weight gain: metabolic implications.
Schizophrenia research 2004;66(2-3):163-7.
2003: Dilip V Jeste; Yoram Barak; Subramoniam Madhusoodanan; Fred Grossman; Georges Gharabawi
International multisite double-blind trial of the atypical antipsychotics risperidone and olanzapine in 175 elderly patients with chronic schizophrenia.
The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 2003;11(6):638-47.
2003: Philip D Harvey; Judy A Napolitano; Lian Mao; Georges Gharabawi
Comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder.
International journal of geriatric psychiatry 2003;18(9):820-9.
1999: F Forette; R Anand; Georges Gharabawi
A phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon).
European journal of neurology : the official journal of the European Federation of Neurological Societies 1999;6(4):423-9.